Healthcare Industry News: antibiotic
News Release - April 19, 2018
BD Unveils Suite of Diagnostic Informatics and Automation InnovationsBD Synapsys™ Microbiology Informatics Solution Among New Offerings Shown at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
FRANKLIN LAKES, N.J., April 19, 2018 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today introduced several new informatics and automation solutions for clinical laboratories, which may play a critical role in the fight against infectious diseases and antimicrobial resistance. The new molecular, microbiology and software solutions will be showcased at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain.
The company announced the plan for the commercial availability of BD Synapsys™ microbiology informatics solution, which provides laboratories with secure connectivity across instruments and locations. The new easy-to-use, browser-based application will help streamline workflows, automate manual processes, and facilitate on-demand actionable insights. Together these capabilities will enable laboratories to improve productivity, simplify compliance, and ultimately get results to clinicians more efficiently.
The BD Synapsys solution will enable on-demand access to data and actionable insights, initially supporting BD BACTEC™ FX systems, BD Kiestra™ solutions, and in the United States BD VeritorTM Plus systems, with plans to include other BD clinical microbiology instruments in the future. This solution helps laboratories and hospitals meet cybersecurity and data privacy standards. The BD Synapsys solution will soon be available in the United States and will be offered in Western Europe and Canada.
"BD understands our lab needs an advanced informatics solution that supports integrated workflow across lab instruments, with access to data across all systems to better utilize our resources, reduce turnaround times and error rates, and show efficiency data in order to maximize the usage of our instrumentation to ultimately allow us to better serve our physicians and patients," said Alanna Emrick, Microbiology Manager at UMC Health System.
Also to be unveiled at the BD booth at ECCMID:
- BD COR™ system is an all new high-throughput molecular platform designed to support a menu of clinically differentiated assays for women's health, sexually transmitted infections and gastrointestinal (GI) applications. The automated system integrates the pre-analytical and analytical steps needed to process samples and provide actionable results, while reducing hands on time for laboratory staff and reducing the potential for manual errors. The BD COR system will be offered in Western Europe beginning in mid-2019 following required regulatory authorization.
- BD Kiestra ID/AST modules will be new additions to the BD Kiestra solution that automate the processing steps for bacterial identification and antibiotic susceptibility testing using the BD Bruker MALDI and BD Phoenix™ systems. These unique laboratory automation solutions use a single organism to ensure that the same bacteria is used in both tests. As with other BD Kiestra modules, the ID/AST modules will drive efficiency in the lab, reduce hands-on time, eliminate errors, and ultimately help clinicians make timely patient management decisions. Upon receiving applicable regulatory authorizations, the BD Kiestra ID module will be offered in early 2019 and the ID/AST module will be available in mid-2019, initially in Europe and Canada. Availability in the U.S. and other regions will follow after regulatory authorizations are secured.
- BD MAX enteric viral panel, available in two configurations. The panels can identify norovirus, rotavirus, adenovirus, sapovirus and human astrovirus, all of which are central to the diagnosis of infectious diarrhea.
- BD MAX Check-Points CPO assay, was developed in conjunction with Check-Points Health B.V. This test provides detection of the five most common carbapenemase genes in approximately 2.5 hours, allowing for the rapid identification of patients colonized with these organisms so that proper infection control measures can be implemented.
BD invites customers and media to join us in ECCMID booth #13 on April 21 at 3:30 p.m. for an innovation celebration with Dave Hickey to learn more about BD's clinical microbiology solutions.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to better diagnose disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
Forward Looking Statements
This press release contains certain forward-looking statements (as defined under Federal securities laws) regarding certain BD product introductions. Forward looking statements may be identified by use of words such as "will", "plan" or other words of similar meaning. All such statements are based upon the current expectations of BD and involve a number of business risks and uncertainties that could cause actual results to differ materially from anticipated results described, implied or projected in any forward-looking statement, including, without limitation, issues relating to regulatory compliance, competition, rapid or unexpected changes in technologies, uncertainties inherent in product development and commercialization, and the ability of our products to gain market acceptance. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
Source: Becton, Dickinson
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.